MDMA-Assisted Psychotherapy (PTSD) — Psychedelics & Neuroplasticity
3,4-methylenedioxymethamphetamine combined with psychotherapy for PTSD — achieved 67% no-longer-meeting-criteria rate in Phase 3 trials; approved in Australia, under FDA review.
Overview
MDMA is an empathogen/entactogen producing intense feelings of emotional openness, trust, empathy, and reduced fear — making it uniquely suited for trauma processing when combined with psychotherapy. MAPS (Multidisciplinary Association for Psychedelic Studies) has conducted Phase 2 and Phase 3 trials showing that 2-3 MDMA sessions embedded in an 8-week psychotherapy course produce dramatic PTSD symptom reduction. The MAPP1 Phase 3 trial (NEJM Evidence 2021, n=90) found 67% of participants no longer met PTSD diagnostic criteria after MDMA-assisted therapy versus 32% with placebo + therapy. A second Phase 3 trial (MAPP2, n=104) confirmed results. FDA advisory committee reviewed in June 2024 and raised concerns about blinding integrity; FDA decision expected 2024-2025. Australia TGA approved MDMA-AT for PTSD in February 2023 — world's first regulatory approval. MDMA acutely reduces amygdala reactivity to threat cues and increases oxytocin, creating a therapeutic window where traumatic memories can be processed with reduced fear response.
Indications
- Chronic PTSD not responding to conventional therapy (EMDR, prolonged exposure, SSRIs)
- Combat-related PTSD (veterans)
- Sexual assault and trauma survivors
- First responder PTSD
- Potentially: end-of-life anxiety, social anxiety in autism spectrum (Phase 2 data)
Mechanism of Action
MDMA causes massive release of serotonin (primary), dopamine, and norepinephrine from nerve terminals, producing the characteristic combination of emotional openness, reduced fear, and increased energy
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| MDMA (clinical trial) | 80-120 mg initial + 40-60 mg supplemental dose (optional, 90-120 min later) | 2-3 sessions over 8-week therapy course, sessions 3-5 weeks apart | Available only in Australia (TGA approved), clinical trials, or expanded access programs; not compounded commercially |
Evidence Grade
GRADE C
Safety & Contraindications
- Cardiovascular: significant hypertension and tachycardia during session — contraindicated in significant cardiovascular disease
- Hyperthermia and serotonin syndrome risk if combined with SSRIs, MAOIs, or other serotonergic agents
- Neurotoxicity concerns at recreational doses (heavy use, overheating) — therapeutic doses with temperature control appear safe
- Contraindicated: uncontrolled hypertension, ischemic heart disease, certain psychiatric conditions (active psychosis, bipolar I)
- Liver toxicity rare; patients with hepatic disease require caution
- Dehydration or hyponatremia possible if fluid intake not appropriately managed